Introduction
============

The process of liver regeneration is, on the molecular level, an extremely complicated process that requires a perfect interplay of cell-cell signaling and gene expression continuity ([@b1-ol-0-0-8108]). Liver regeneration has traditionally been divided into three phases: Initiation, proliferation and termination ([@b2-ol-0-0-8108]). The duration of these phases depends on the organism under examination, including human, pig or rat, and the type of surgical intervention, including partial hepatectomy, intoxication by drugs, or hereditary predispositions ([@b3-ol-0-0-8108]). The organisms most frequently used to investigate liver regeneration are rats and mice, which are relatively well-investigated model organisms. However, pigs (*Sus scrofa*) are anatomically and physiologically closer to humans than rodents, and therefore are attractive subjects for biomedical research, despite the higher cost of maintenance ([@b4-ol-0-0-8108]). Budai *et al* ([@b5-ol-0-0-8108]) outlines a detailed comparison of existing associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) animal models and their advantages.

Currently, it is known that application of adipose-derived stem cells may positively modulate tissue regeneration processes ([@b6-ol-0-0-8108]--[@b8-ol-0-0-8108]). There are a number of clinical studies that are aimed at verifying the safety and effectiveness of this form of treatment; however, the molecular mechanisms of action remain largely unclear ([@b9-ol-0-0-8108],[@b10-ol-0-0-8108]). It is likely to be the primarily paracrine mechanism of action that produces growth factors and cytokines, which positively modulate regenerative processes, such as improved angiogenesis, and limit inflammatory processes ([@b9-ol-0-0-8108],[@b10-ol-0-0-8108]).

The present study analyzed the effect of the application of stromal vascular fat tissue stem cells on liver regeneration during the first stage of ALPPS procedure. ALPPS is a relatively recent modification of the two-staged hepatectomy, first described in 2010 ([@b11-ol-0-0-8108]). ALPPS approach allows for surgery on severe liver tumor burden in two associated steps. In the first step, tumor loci are removed from less affected liver lobe, the two liver lobes are split by parenchyma transection and the more metastatic region of the liver is deportalized. Deportalization of one liver lobe stimulates the second liver lobe to undergo hypertrophic regeneration (the future liver remnant). The patient is then permitted 1 or 2 weeks to recover. The second step removes the deportalized region of the liver, while the hypertrophic future liver remnant is fully functional ([@b12-ol-0-0-8108]). This approach significantly increases possibility of curative treatment of severe liver tumor diseases ([@b13-ol-0-0-8108]).

It is assumed that the application of stem cells obtained from stromal vascular fat tissue accelerates the regenerative process by allowing for improved angiogenesis and modulation of inflammation, as has been previously observed in animal-model studies ([@b14-ol-0-0-8108],[@b15-ol-0-0-8108]); however, to the best of our knowledge, this has not been demonstrated in direct connection with ALPPS approach and *Sus scrofa* model organism. The aim of the present study was to identify candidate genes that may be used as screening markers for monitoring the process of liver regeneration following the first stage of ALPPS.

Materials and methods
=====================

### Animals

A total of six juvenile domestic swine (Polish white pigs; 6 months; seven females and one castrated male; weight 30--50 kg; Instytut Zootechniki, Grodziec Ślaski, Poland) were included in the present study. The pigs were housed in separated boxes at room temperature (15--20°C), air humidity of 50--60%, normal atmosphere, 12 h light/dark cycles and access to food and water *ad libidum*. Procedures were performed in the Center for Cardiovascular Research and Development, American Heart of Poland S.A. (Ustroń, Poland) between September and October 2014. Approval from the Bioethical Committee from the Center for Cardiovascular Research and Development, American Heart of Poland S.A. (Ustroń, Poland) was obtained. Animals were assigned to two groups: n=3 without stem cell application (pig nos. 1--3) and n=3 with stem cell application (pig nos. 4--6), based on their identification numbers. All animals received an acclimation period of 3 days prior to any procedures, during which and no premedication was administered. Animals were anesthetized following an overnight fast (water was not withheld) based on their body weight using ketamine (20 mg/kg), xylazine (2 mg/kg) and atropine (1 mg/pig). Propofol was also administered as a bolus (1 mg/kg) prior to intubation to induce muscle relaxation. General anesthesia was maintained during procedures with a constant infusion drip of propofol. Fentanyl (100 µg/pig) was administered at the beginning of each procedure to potentiate anesthesia and as an analgesic, and all animals received mechanical ventilation support throughout the procedures. At pre-determined time-points the animals were euthanized with pentobarbital solution (140 mg/kg), and livers were harvested for histological and whole transcriptome analysis. Pigs were necropsied and examined for abnormal findings, and were labeled with the animal identification number, protocol number and date of collection.

### ALPPS first phase

Pigs were anaesthetized as aforementioned. Laparotomy and investigation of the abdominal organs was performed, and revision of the liver was conducted, with the preparation of the liver hilus, identification of the portal vein and its branching, identification of the bile duct and hepatic arteries. Confirmation of the injection site was performed by venography using contrast medium (iopromidum) and C-arm fluoroscopy. The entry of hepatic veins into vena cava inferior was identified. The flow of portal blood into four lobes of the liver was interrupted; only the inflow of portal blood into the one selected hepatic lobe (future liver remnant) was preserved. This procedure was followed by splitting of liver between the lobe with preserved perfusion through the portal vein and other lobes, to which the inflow of portal blood was closed. Samples of liver tissue were harvested from the future liver remnant lobes and were stored snap-frozen using liquid nitrogen (−196°C) in a tissue bank. Furthermore, 15 ml of the human adipose stem cells-stromal vascular fraction concentrate (Cytori Therapeutics, Inc., San Diego, CA, USA) was administered intra-arterially to the group of animals with planned administration of stem cells via the hepatic artery during the surgery procedure. For more information about characteristics of this concentrate see a previous study by Lin *et al* ([@b16-ol-0-0-8108]). The animals in the group that did not undergo stem cell application were administered 15 ml of saline via an identical route of administration. Hydrocortisone was applied intravenously prior to the administration of stem cells to prevent an autoimmune reaction (rejection). The animals were monitored postoperatively by measuring body temperature (*per rectum*) and weight daily.

### ALPPS second phase

Surgery was performed 9 days after the first stage. Re-laparotomy and investigation of abdominal organs were performed, together with liver revision and identification of pre-marked structures in the hilus and entry of hepatic veins into the vena cava inferior. In total, four liver lobes were removed with the perfused lobe remaining in place.

### Tissue sampling, RNA isolation and whole transcriptome sequencing

All samples of liver tissue were collected into separate 5 ml polypropylene tubes prefilled with equivalent volume of RNA later solution and stored at −20°C. Isolation of total RNA was performed using the QuickGene Mini 80 semiautomatic device and appropriate RNA tissue kit SII (both from Kurabo Industries Ltd., Osaka, Japan). RNA concentration and integrity were determined using the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA). RNA-sequencing libraries preparation and cDNA sequencing was performed by Macrogen, Inc. (Seoul, Republic of Korea), resulting in a set of 101 nucleotide paired-end-read data files.

### Transcriptome data analysis

The quality of the raw sequencing data was assessed using FastQC (v0.11.5) ([@b17-ol-0-0-8108]) and aligned to a reference genome of *Sus scrofa* (Ensembl v82; *Sus scrofa* 10.2) using the STAR aligner (v2.4.1b) ([@b18-ol-0-0-8108]). Up to five mapping reads were used for subsequent analyses. Raw gene counts were obtained by calculating reads mapping to exons and summarized by genes using reference gene annotation (Ensembl v.82, *Sus scrofa* assembly, GTF) by featureCounts (v1.4.6-p5) ([@b19-ol-0-0-8108]). Differential gene expression was calculated using edgeR (v3.10.5) ([@b20-ol-0-0-8108]). Two states (day 0 and 9) within each experimental group of animals were compared. False discovery rate (FDR) correction was used to correct the P-values for multiple assessments. Genes were determined as differentially expressed when the FDR adjusted P-value ≤0.1 and log~2~ fold-change (log~2~FC) ≥0.5. Pathway analyses were performed in STRING (v10.5) ([@b21-ol-0-0-8108],[@b22-ol-0-0-8108]), Panther ([@b23-ol-0-0-8108]) with the aid of Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@b24-ol-0-0-8108],[@b25-ol-0-0-8108]).

### Volumetric measurements

All magnetic resonance imaging (MRI) experiments were performed using a 1.5 T scanner (GE Healthcare, Chicago, IL, USA), and an eight-channel phased array head coil was used. MRI measurements were performed at baseline (day 0) and on day 9, prior to second ALPPS stage.

### Statistical analysis

The non-parametric paired Wilcoxon test was used for statistical comparison of changes in liver volume between day 0 and 9. According to the experimental design, this comparison was performed separately for the group that did not receive the application of stem cells and for the group that did. Software R was used for statistical analysis (version 3.4.1; The R Foundation for Statistical Computing, Wien, Austria). P\<0.05 was considered to indicate a statistically significant difference. Data in the barplots are presented as the mean ± standard deviation.

Results
=======

Although each step of the ALPPS procedure was performed successfully, no significant changes in total liver volume were observed following the first ALPPS stage ([Fig. 1](#f1-ol-0-0-8108){ref-type="fig"}) (P=0.5 without application of stem cells; P=0.75 with application of stem cells). This may be due to the fact that only future liver remnants are expected to increase in size over a longer period of time.

Comprehensive transcriptome analysis of samples from future liver remnant was performed to examine for changes in the gene expression between groups with and without application of stem cells. We hypothesized that the application of stem cells would accelerate liver regeneration by inhibition of undesirable processes, such as fibrosis and inflammation.

A total of 39 significantly differentially expressed genes were identified in the group without application of stem cells between day 0 and 9 ([Table I](#tI-ol-0-0-8108){ref-type="table"}), there of 37 genes were upregulated and two downregulated. In the group with stem cell treatment there were no differentially expressed genes between day 0 and 9. The highest significantly different gene expression was observed for collagen type IV α1 chain (COL4A1). COL4A1, COL4A2, laminin subunit γ1 and nidogen 2 (all of which were upregulated; [Fig. 2](#f2-ol-0-0-8108){ref-type="fig"}) form major components of the basement membrane (with COL4A1 and COL4A2 constituting a functional heterotrimer with 2:1 stoichiometry) ([@b26-ol-0-0-8108],[@b27-ol-0-0-8108]). The greatest positive change (upregulation) in the gene expression was for latent transforming growth factor-β binding protein 2 (LTBP2) and the greatest negative change (downregulation) was for heme binding protein 2. LTBP2 together with thrombospondin 1, transglutaminase 2 and fibrillin 1, all of which were upregulated (detailed changes in gene expression are depicted in [Fig. 3](#f3-ol-0-0-8108){ref-type="fig"}) and serve an important role in the transforming growth factor-β pathway in the extracellular matrix remodeling process ([@b28-ol-0-0-8108]).

Functional classification revealed that the majority of differentially expressed genes from the group of pigs that received the application of stem cells are associated with their functional interactions and localization (primarily in the extracellular matrix and cytoplasmic membrane); [Fig. 4](#f4-ol-0-0-8108){ref-type="fig"} contains a detailed interactome, with mainly collagens making up a strong interaction network. Analysis of molecular functions revealed 19 significantly enrichment categories, as 'growth factor binding', 'extracellular matrix structural constituent' or 'semaphorin receptor activity' ([Table II](#tII-ol-0-0-8108){ref-type="table"}). This is in congruence with a previous study by Rychtrmoc *et al* ([@b29-ol-0-0-8108]), where they observed changes in expression in a number of genes involved in extracellular matrix remodeling pathways in liver regeneration termination using microarray and reverse transcription-quantitative polymerase chain reaction analysis in a rat model ([@b29-ol-0-0-8108]). At the level of biological processes the most relevant significantly enriched categories were 'anatomical structure morphogenesis', 'circulatory system development' and 'axon development' ([Table III](#tIII-ol-0-0-8108){ref-type="table"}). The most enriched KEGG pathways were 'PI3K-Akt signaling pathway', 'Focal adhesion' and 'ECM-receptor interaction' ([Table IV](#tIV-ol-0-0-8108){ref-type="table"}). The phosphoinositide 3-kinase (PI3K)-RAC serine/threonine-protein kinase (Akt) signaling pathway is likely to drive forward liver regeneration via hepatocyte growth factor stimulation, as observed on rat oval cells *in vitro* ([@b30-ol-0-0-8108]). Inhibition of the PI3K-Akt pathway disturbed liver regeneration in mice ([@b31-ol-0-0-8108]).

A more detailed examination of gene expression in specific pigs between day 0 and 9 revealed certain notable facts (only values with a log~2~ FC ± 3 with \>4 normalized edgeR counts were taken into account). Only certain genes in pig nos. 4 and 6 (that received stem cell treatment) met these more stringent criteria ([Table V](#tV-ol-0-0-8108){ref-type="table"}). In pig no. 6, there was an extremely large increase in the expression of the RNA component of RNase P and 7S kinase (7SK) RNA. According to Reiner *et al* ([@b32-ol-0-0-8108]), RNase P may serve an important role in transcription of a number of non-coding RNAs that are transcribed by RNA polymerase III. 7SK RNA is one of the genes transcribed by RNA polymerase III. It is therefore likely that in pig no. 6 there was co-expression of these two genes, which are localized on the same chromosome (RNase P RNA component, chromosome 7:83, 579, 873--83, 580, 200 forward strand; 7SK RNA, chromosome 7:134, 400, 749--134, 401, 079 forward strand). There were also three overexpressed genes for Metazoan signal recognition particle RNA (also transcribed by RNA polymerase III). Interleukin-13 receptor subunit α2 was also downregulated in pig no. 6. However, these results for individual pigs cannot conclusively inform on the mode of action of the applied stem cells, but serve as a source of hypotheses for subsequent studies.

Discussion
==========

Although the liver has the ability to regenerate itself, the application of stem cells speeds up the process; this has been demonstrated in the present study via the presence of fewer differentially expressed genes in the presence of stem cells, indicating that the regeneration process is finished or is in the late phase. Timing is crucial in the ALPPS procedure, so faster liver regeneration between stages is highly beneficial. According to the experimental design, no significant changes to liver morphology were expected; as 9 days is too short a period to observe liver fibrosis ([@b33-ol-0-0-8108]--[@b37-ol-0-0-8108]), gene expression analyses were performed, which reliably identify expression changes in collagen and other fibrogenic factors before they become visible via microscopy. Previous animal studies demonstrated that microscopic changes to liver structure following intervention were not observed for several weeks ([@b33-ol-0-0-8108]--[@b37-ol-0-0-8108]).

Differentially expressed genes in the group of pigs that did not receive stem cell application (between day 0 and 9) encode proteins primarily involved in extracellular matrix remodeling, angiogenic and neurogenic processes. Owing to the fact that in the group that underwent the application of stem cells, there were no differentially expressed genes between day 0 and 9, the application of stem cells seemingly positively modulated the regenerative processes by accelerating regeneration, and preventing an unwanted fibrosis and inflammation processes. To provide more precise interpretation a larger number of biological replicates and more time-points are required (ideally on day 0, 3, 5, 7, 9, 11 and 20 to observe upward/downward trends in gene expression in broader time scale), although in a large animal model, such an approach is limited by financial costs.

Angiogenesis is a process that accompanies liver regeneration process and serves an important role in restoration of vascular networks in the place of liver damage. This process is driven by several pro-angiogenic growth factors. A number of the primary pro-angiogenic factors are vascular endothelial growth factors that bind to their membrane receptors, including Fms-related tyrosine kinase-1 (Flt-1), fetal liver kinase-1 or Flt-4. The present study observed the increased expression of Flt-1 receptor in the group without application of stem cells between day 0 and 9, which is in congruence of former study in a rat model, in which expression of Flt-1 was significantly increased between day 4 and 10 following 70% hepatectomy ([@b38-ol-0-0-8108]).

The process of axon guidance in liver regeneration may be mediated by secreted third class semaphorins (Sema3A-G), which bind to a membrane receptor complex whose main component is a transmembrane glycoprotein neuropillin 1 or neuropillin 2, or a heterodimer of the two ([@b39-ol-0-0-8108]). The interaction between the semaphorins 3A and neuropillin 1 is also notable in the angiogenic processes ([@b40-ol-0-0-8108]). The present study revealed increased expression of neuropillin 1 and neuropillin 2 in the group without application of stem cells between day 0 and 9.

The remodeling of extracellular matrix serves an important role in the process of liver regeneration. In the initiation stage of liver regeneration, the extracellular matrix is broken down to allow for the proliferation of hepatocytes. Subsequently, the extracellular matrix requires rebuilding to ensure physical support is provided to endothelial cells. Production of extracellular matrix is primarily provided by the population of stellar liver cells. Restoration of the extracellular matrix is manifested by an increased synthesis of collagen, structural glycoproteins and proteoglycans, which occurs mainly between day 3 and 5 following partial hepatectomy in a rat model ([@b41-ol-0-0-8108]). The present study observed an elevated expression of a number of genes associated with extracellular matrix remodeling between day 0 and day 9 day in the group without application of stem cells.

The application of stem cells in pig no. 6 (that received the application of stem cells) likely decreased the expression of interleukin 13 receptor subunit α2 (IL13RA2). Functional IL13RA2 was overexpressed in activated hepatic stellate cells in rat livers ([@b42-ol-0-0-8108]). Activated hepatic stellate cells are associated with unwanted liver fibrosis ([@b43-ol-0-0-8108]). The anti-fibrotic effect of xenogeneic adipose mesenchymal stem cells was recently observed by Maria *et al* ([@b44-ol-0-0-8108]), whereby a mouse model of systemic sclerosis was used. It would be necessary to use more biological replicates than in the present study to determine more accurately the number of pigs in which this effect occurred. In pig no. 6, rapid co-expression of RNAseP and 7SK functional RNAs (\>16 times higher expression) was observed. It would be interesting to examine this observation in similar experiments in the future. However, owing to the limited number of biological replicates, clear interpretation cannot be performed. It is possible, that RNAseP may serve as a major inductor of 7SK RNA expression, as, according to Reiner *et al* ([@b32-ol-0-0-8108]), RNAseP activates the transcription of RNA polymerase III.

The change in gene expression in pig no. 4 that underwent application of stem cells likely demonstrates the termination of proliferative processes, characterized by the downregulation of Mdm4 p53 binding protein homolog (mouse) and LATS large tumor suppressor homolog 1 (*Drosophila*) and thereby stabilization of the p53 suppressor protein. This also reflects the decreased expression of other transcription factors, including one cut homeobox 1 (ONECUT1) or heart development protein with EGF like domains 1. The overexpression of ONECUT1 was observed in early stages of liver regeneration in a rat model ([@b45-ol-0-0-8108]). SH3 and PX domains 2A is apparently involved in the production of free radicals as a member of the NADPH oxidase complex complex ([@b46-ol-0-0-8108]). This finding indicates that the proliferative processes in pig no. 4 were accelerated owing to the application of stem cells and similarly, the formation of undesirable free radicals was limited.

RNA sequencing studies aided the evaluation of gene expression in animal models of variety human clinical conditions, including in the study by Arvaniti *et al* ([@b47-ol-0-0-8108]), which revealed numerous previously unknown genes associated with renal fibrosis using a mouse model ([@b47-ol-0-0-8108]). Although the present study encountered limitations including the mortality of one pig due to source contamination and also the corruption of one sequenation data file. These limitations resulted in decreased animal numbers; however, the results obtained may provide insight and could be validated by future studies that build on these findings. Certain differentially expressed genes identified in the present study may serve as molecular markers for monitoring the progress of liver regeneration generally, not only during ALPPS, in human patients. Analysis of differentially expressed genes indicates that the application of stem cells elicited a positive effect in the acceleration of regenerative processes; however, there is a requirement for further experiments to be conducted with more biological replicates and tissue sampling time-points.
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![Total liver volume measurement by magnetic resonance imaging in the group that did not receive stem cell application (left side; paired Wilcoxon test, P=0.23) and the group that did (right side; paired Wilcoxon test, P=0.65). Dashed lines illustrate sample pairing. Measurements were made prior to the first stage (day 0) and prior to the second stage (day 9) of ALPPS. In the two cases, paired t-test P-values were not significant, which was likely due to low number of biological replicates.](ol-15-05-6309-g00){#f1-ol-0-0-8108}

![Significantly differentially expressed genes of the 'basement membrane cluster' in the all groups between day 0 and day 9, within groups only. The plot shows the mean values and standard deviations (\*P\<0.05, \*\*P\<0.01 and \*\*\*P\<0.001 vs. corresponding control - day 0).](ol-15-05-6309-g01){#f2-ol-0-0-8108}

![Significantly differentially expressed genes of the 'TGF-β affecting cluster' in the all groups between day 0 and 9, within groups only. The plot shows the mean values and standard deviations (\*P\<0.05 and \*\*P\<0.01).](ol-15-05-6309-g02){#f3-ol-0-0-8108}

![Protein-protein interaction network of 39 significantly differentially expressed genes in the group without application of stem cells (between day 0 and 9). Individual clusters represent structurally or functionally similar proteins (black circles stands for 'collagen' cluster, gray for 'neural and vascular development' cluster, striped for 'TGF-β affecting' cluster and white for 'Other basement membrane proteins' cluster. Thickness of connecting lines depends on the degree of scientific evident for particular connection. Figure was constructed in STRING online v.10.5 ([@b21-ol-0-0-8108],[@b22-ol-0-0-8108]). Disconnected nodes are hidden. Four clusters were made using built in 'k means clustering' function.](ol-15-05-6309-g03){#f4-ol-0-0-8108}

###### 

Significantly differentially expressed genes in the group without application of stem cells between day 0 and 9, sorted by lowest FDR value.

  Identifier           Symbol     Gene name                                                log~2~ FC   FDR
  -------------------- ---------- -------------------------------------------------------- ----------- ------
  ENSSSCG00000009544   COL4A1     Collagen, type IV, α1                                    0.93        0.00
  ENSSSCG00000007000   FAT1       FAT tumor suppressor homolog 1 (*Drosophila*)            0.78        0.01
  ENSSSCG00000000712   VWF        Von Willebrand factor                                    1.15        0.01
  ENSSSCG00000023522   TGM2       Transglutaminase 2                                       0.75        0.01
  ENSSSCG00000004658   FBN1       Fibrillin 1                                              0.94        0.01
  ENSSSCG00000011859   HEG1       HEG homolog 1 (zebrafish)                                0.95        0.01
  ENSSSCG00000001725   GPR116     G protein-coupled receptor 116                           0.69        0.01
  ENSSSCG00000009545   COL4A2     Collagen, type IV, α2                                    0.84        0.01
  ENSSSCG00000014442   PDGFRB     Platelet-derived growth factor receptor, β-polypeptide   0.82        0.01
  ENSSSCG00000028022   COL6A2     Collagen, type VI, α2                                    0.74        0.02
  ENSSSCG00000002368   LTBP2      Latent transforming growth factor-β binding protein 2    1.64        0.02
  ENSSSCG00000004150   HEBP2      Heme binding protein 2                                   −1.09       0.02
  ENSSSCG00000008749   SLIT2      Slit homolog 2 (*Drosophila*)                            1.28        0.02
  ENSSSCG00000011443   STAB1      Stabilin 1                                               0.84        0.02
  ENSSSCG00000005751   COL5A1     Collagen, type V, α1                                     0.76        0.03
  ENSSSCG00000009045   HHIP       Hedgehog interacting protein                             0.71        0.03
  ENSSSCG00000004387   FOXO3A     Forkhead box O3                                          0.65        0.04
  ENSSSCG00000001834   MFGE8      Milk fat globule-EGF factor 8 protein                    0.74        0.04
  ENSSSCG00000027969   AHNAK      AHNAK nucleoprotein                                      0.91        0.04
  ENSSSCG00000009320   FLT1       Fms-related tyrosine kinase 1                            0.85        0.04
  ENSSSCG00000004091   AKAP12     A kinase (PRKA) anchor protein 12                        0.81        0.04
  ENSSSCG00000028239   FBXL7      F-box and leucine-rich repeat protein 7                  1.10        0.04
  ENSSSCG00000011075   KIAA1217   Kiaa1217                                                 0.61        0.04
  ENSSSCG00000022000   COL1A2     Collagen, type I, α2                                     0.80        0.05
  ENSSSCG00000029189   DCHS1      Dachsous 1 (*Drosophila*)                                0.91        0.05
  ENSSSCG00000017548   NGFR       Nerve growth factor receptor                             0.79        0.05
  ENSSSCG00000009111   SYNPO2     Synaptopodin 2                                           0.91        0.06
  ENSSSCG00000015068   APOA4      Apolipoprotein A-IV                                      −0.62       0.06
  ENSSSCG00000015555   LAMC1      Laminin, γ1                                              0.74        0.07
  ENSSSCG00000005030   NID2       Nidogen 2 (osteonidogen)                                 0.68        0.07
  ENSSSCG00000011102   NRP1       Neuropilin 1                                             0.55        0.08
  ENSSSCG00000026383   NRP2       Neuropilin 2                                             0.78        0.08
  ENSSSCG00000015326   COL1A2     Collagen, type I, α2                                     0.78        0.09
  ENSSSCG00000027331   COL6A3     Collagen, type VI, α3                                    0.71        0.09
  ENSSSCG00000011743   MECOM      MDS1 and EVI1 complex locus                              1.28        0.09
  ENSSSCG00000005494   TNC        Tenascin C                                               1.40        0.10
  ENSSSCG00000015426   RELN       Reelin                                                   0.61        0.10
  ENSSSCG00000016035   COL5A2     Collagen, type V, α2                                     0.67        0.10
  ENSSSCG00000004789   THBS1      Thrombospondin 1                                         1.10        0.10

Log~2~FC \>\|0.5\| and FDR \<0.1 were chosen as a threshold. log~2~FC, log~2~ fold change; FDR, false discovery rate.

###### 

Molecular function enrichment in the group without application of stem cells between day 0 and 9, sorted by FDR value.

  Pathway ID   Pathway description                                              Observed gene count   FDR           Matching proteins
  ------------ ---------------------------------------------------------------- --------------------- ------------- -----------------------------------------------------------------------------------------------------------------------------------------------
  GO.0019838   Growth factor binding                                            8                     5.25×10^−9^   COL1A2, COL4A1, COL5A1, FLT1, NRP1, NRP2, DGFRB, THBS1
  GO.0048407   Platelet-derived growth factor binding                           4                     4.28×10^−6^   COL1A2, COL4A1, COL5A1, PDGFRB
  GO.0005539   Glycosaminoglycan binding                                        7                     3.18×10^−5^   COL5A1, LTBP2, NRP1, NRP2, SLIT2, STAB1, THBS1
  GO.0005201   Extracellular matrix structural constituent                      5                     6.82×10^−5^   COL1A2, COL4A1, COL4A2, COL5A1, FBN1
  GO.0097493   Structural molecule activity conferring elasticity               3                     6.88×10^−5^   AHNAK, COL4A1, FBN1
  GO.0005021   Vascular endothelial growth factor-activated receptor activity   3                     8.59×10^−5^   FLT1, NRP1, NRP2
  GO.0008201   Heparin binding                                                  6                     8.59×10^−5^   COL5A1, LTBP2, NRP1, NRP2, SLIT2, THBS1
  GO.0005515   Protein binding                                                  21                    0.000139      AHNAK, AKAP12, APOA4, COL1A2, COL4A1, COL5A1, FBN1, FLT1, FOXO3, HHIP, MECOM, NGFR, NID2, NRP1, NRP2, PDGFRB, RELN, SLIT2, SYNPO2, THBS1, TNC
  GO.0005509   Calcium ion binding                                              9                     0.00039       DCHS1, FAT1, FBN1, HEG1, LTBP2, MECOM, NID2, SLIT2, THBS1
  GO.0043394   Proteoglycan binding                                             3                     0.000866      COL5A1, SLIT2, THBS1
  GO.0004714   Transmembrane receptor protein tyrosine kinase activity          4                     0.00106       FLT1, NRP1, NRP2, PDGFRB
  GO.0030023   Extracellular matrix constituent conferring elasticity           2                     0.0044        COL4A1, FBN1
  GO.0038085   Vascular endothelial growth factor binding                       2                     0.0044        NRP1, PDGFRB
  GO.0046872   Metal ion binding                                                17                    0.0117        APOA4, COL1A2, COL5A1, DCHS1, FAT1, FBN1, HEG1, HHIP, LTBP2, MECOM, NID2, NRP1, NRP2, RELN, SLIT2, TGM2, THBS1
  GO.0017154   Semaphorin receptor activity                                     2                     0.0259        NRP1, NRP2
  GO.0019955   Cytokine binding                                                 3                     0.0335        NRP1, NRP2, THBS1
  GO.0005178   Integrin binding                                                 3                     0.0461        COL5A1, FBN1, THBS1
  GO.0005198   Structural molecule activity                                     6                     0.0461        AHNAK, COL1A2, COL4A1, COL4A2, COL5A1, FBN1
  GO.0030169   Low-density lipoprotein particle binding                         2                     0.0476        STAB1, THBS1

FDR=0.05 was chosen as a threshold. FDR, false discovery rate.

###### 

Biological process enrichment in the group without application of stem cells between day 0 and 9, sorted by lowest FDR value.

  Pathway ID   Pathway description                              Observed gene count   FDR            Matching proteins
  ------------ ------------------------------------------------ --------------------- -------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  GO.0009653   Anatomical structure morphogenesis               21                    7.36×10^−10^   COL1A2, COL4A1, COL4A2, COL6A2, COL6A3, DCHS1, FAT1, FBN1, FLT1, FOXO3, HEG1, HHIP, MECOM, NGFR, NRP1, NRP2, PDGFRB, SLIT2, TGM2, THBS1, TNC
  GO.0072358   Cardiovascular system development                14                    1.8×10^−8^     COL1A2, COL4A1, COL4A2, COL5A1, DCHS1, FBN1, FLT1, HEG1, MECOM, NRP1, NRP2, PDGFRB, SLIT2, THBS1
  GO.0072359   Circulatory system development                   14                    1.8×10^−8^     COL1A2, COL4A1, COL4A2, COL5A1, DCHS1, FBN1, FLT1, HEG1, MECOM, NRP1, NRP2, PDGFRB, SLIT2, THBS1
  GO.0044243   Multicellular organismal catabolic process       7                     1.38×10^−7^    APOA4, COL1A2, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3
  GO.0001568   Blood vessel development                         11                    1.51×10^−7^    COL1A2, COL4A1, COL4A2, COL5A1, FLT1, HEG1, NRP1, NRP2, PDGFRB, SLIT2, THBS1
  GO.0001944   Vasculature development                          11                    1.58×10^−7^    COL1A2, COL4A1, COL4A2, COL5A1, FLT1, HEG1, NRP1, NRP2, PDGFRB, SLIT2, THBS1
  GO.0006935   Chemotaxis                                       12                    1.58×10^−7^    COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, FLT1, NGFR, NRP1, NRP2, PDGFRB, RELN, SLIT2
  GO.0030198   Extracellular matrix organization                10                    1.72×10^−7^    COL1A2, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, FBN1, NID2, THBS1, TNC
  GO.0061564   Axon development                                 11                    2.00×10^−7^    COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, NGFR, NRP1, NRP2, RELN, SLIT2, TNC
  GO.0007411   Axon guidance                                    10                    3.15×10^−7^    COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, NGFR, NRP1, NRP2, RELN, SLIT2
  GO.0022617   Extracellular matrix disassembly                 7                     5.34×10^−7^    COL1A2, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, FBN1
  GO.0040011   Locomotion                                       14                    6.1×10^−7^     COL1A2, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, FAT1, FLT1, NGFR, NRP1, PDGFRB, SLIT2, THBS1
  GO.0048666   Neuron development                               12                    1.04×10^−6^    APOA4, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, MECOM, NGFR, NRP1, NRP2, SLIT2, TNC
  GO.0030574   Collagen catabolic process                       6                     1.23×10^−6^    COL1A2, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3
  GO.0071363   Cellular response to growth factor stimulus      11                    1.3×10^−6^     COL1A2, COL4A2, FBN1, FLT1, FOXO3, LTBP2, MECOM, NGFR, NRP1, NRP2, PDGFRB
  GO.0000904   Cell morphogenesis involved in differentiation   11                    1.57×10^−6^    COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, HEG1, NGFR, NRP1, NRP2, RELN, SLIT2
  GO.0007409   Axonogenesis                                     10                    1.57×10^−6^    COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, NGFR, NRP1, NRP2, RELN, SLIT2
  GO.0031175   Neuron projection development                    11                    1.57×10^−6^    APOA4, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, NGFR, NRP1, NRP2, SLIT2, TNC
  GO.0006928   Movement of cell or subcellular component        14                    1.58×10^−6^    COL1A2, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, FAT1, FLT1, NGFR, NRP1, NRP2, PDGFRB, SLIT2, THBS1
  GO.0048468   Cell development                                 15                    1.79×10^−6^    APOA4, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, FOXO3, HEG1, MECOM, NGFR, NRP1, NRP2, PDGFRB, SLIT2, TNC

The 20 best hits are shown. FDR, false discovery rate.

###### 

Kyoto Encyclopedia of Genes and Genomes pathway enrichment in the group without application of stem cells between day 0 and 9, sorted by lowest FDR value.

  Pathway ID   Pathway description                Observed gene count   FDR            Matching proteins
  ------------ ---------------------------------- --------------------- -------------- --------------------------------------------------------------------------------------------
  4151         PI3K-Akt signaling pathway         13                    9.81×10^−13^   COL1A2, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, FLT1, FOXO3, NGFR, PDGFRB, RELN, HBS1, TNC
  4510         Focal adhesion                     11                    1.49×10^−12^   COL1A2, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, FLT1, PDGFRB, RELN, THBS1, TNC
  4512         ECM-receptor interaction           9                     1.49×10^−12^   COL1A2, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3, RELN, THBS1, TNC
  4974         Protein digestion and absorption   6                     3.52×10^−7^    COL1A2, COL4A1, COL4A2, COL5A1, COL6A2, COL6A3
  5146         Amoebiasis                         4                     0.00149        COL1A2, COL4A1, COL4A2, COL5A1
  5200         Pathways in cancer                 5                     0.00832        COL4A1, COL4A2, HHIP, MECOM, PDGFRB
  4015         Rap1 signaling pathway             4                     0.0144         FLT1, NGFR, PDGFRB, THBS1

FDR=0.05 was chosen as a threshold. FDR, false discovery rate.

###### 

Differentially expressed genes in pig nos. 4 and 6 (that received stem cell treatment) between the day 0 and 9, sorted by highest Log~2~FC value.

  Identifier           Symbol           Gene name                                                         log~2~FC
  -------------------- ---------------- ----------------------------------------------------------------- ----------
  ENSSSCG00000019556   7SK              7SK RNA                                                           4.11
  ENSSSCG00000020439   RNaseP_nuc       Nuclear RNase P                                                   4.02
  ENSSSCG00000024699   Metazoa_SRP      Metazoan signal recognition particle RNA                          3.48
  ENSSSCG00000029839   Metazoa_SRP      Metazoan signal recognition particle RNA                          3.47
  ENSSSCG00000029605   Metazoa_SRP      Metazoan signal recognition particle RNA                          3.06
  ENSSSCG00000012594   IL13RA2          Interleukin 13 receptor subunit α2                                −3.09
  ENSSSCG00000029023   ARL5B            ADP-ribosylation factor-like 5B                                   −5.43
  ENSSSCG00000008595   APOB             Apolipoprotein B                                                  −3.73
  ENSSSCG00000002387   GPATCH2L         G patch domain containing 2-like                                  −3.59
  ENSSSCG00000030247   EPM2AIP1         EPM2A (laforin) interacting protein 1                             −3.57
  ENSSSCG00000024674   ABL2             v-abl Abelson murine leukemia viral oncogene homolog2             −3.48
  ENSSSCG00000030726   CH242-150C11.4   CH242-150C11.4                                                    −3.46
  ENSSSCG00000005466   ROD1             PTBP3-polypyrimidine tract binding protein 3                      −3.23
  ENSSSCG00000016510   UBN2             Ubinuclein 2                                                      −3.19
  ENSSSCG00000008909   CLOCK            Clock homolog (mouse)                                             −3.17
  ENSSSCG00000004616   ONECUT1          One cut homeobox 1                                                −3.12
  ENSSSCG00000015284   MDM4             Mdm4 p53 binding protein homolog (mouse)                          −3.10
  ENSSSCG00000008292   TET3             Tet methylcytosine dioxygenase 3                                  −3.09
  ENSSSCG00000016119   RAPH1            Ras association (RalGDS/AF-6) and pleckstrin homology domains 1   −3.09
  ENSSSCG00000004106   LATS1            LATS, large tumor suppressor, homolog 1 (*Drosophila*)            −3.08
  ENSSSCG00000010604   SH3PXD2A         SH3 and PX domains 2A                                             −3.07
  ENSSSCG00000025182   ELK4             ELK4, ETS-domain protein (SRF accessory protein 1)                −3.04
  ENSSSCG00000002755   NFAT5            Nuclear factor of activated T-cells 5, tonicity-responsive        −3.03
  ENSSSCG00000016031   CRLR             Calcitonin receptor-like                                          −3.02
  ENSSSCG00000005285   GNAQ             Guanine nucleotide binding protein (G protein), q polypeptide     −3.02

Only values of log~2~FC higher than ±3 with more than four normalized edgeR counts were taken into account. Log~2~FC, log~2~ fold change.
